Diane Bieri

American Urological Association and Urology Care Foundation, Arnold & Porter Kaye Scholer (Washington)
General Counsel

Diane is a senior trade association executive and legal counsel with broad experience advocating for companies and individuals in the health care and life sciences sectors. In her current role, Ms. Bieri counsels the American Urological Association and Urology Care Foundation, supervising all aspects of the society’s legal work. Previously, she served as outside counsel to multinational companies on antitrust, FDA, and health care compliance issues, and represented companies and associations in antitrust and other complex litigation. As former lead counsel of another influential trade association, she collaborated with other senior leaders to set strategic priorities, allocate and manage resources and advance policy positions that facilitate the development of life-saving medicines in the U.S. and internationally. She led, recruited, and retained a talented legal team, and led the association to significant legal victories, including a successful Supreme Court challenge overturning a Vermont marketing statute. Ms. Bieri is an experienced advocate, comfortable representing her clients before courts, legislatures, agencies, the media and other stakeholders. Ms. Bieri earned her law degree from the Georgetown University Law Center where she was a member of the Georgetown Law Journal.

Linked authors

Arnold & Porter Kaye Scholer (Brussels)
Latham & Watkins (San Francisco)
Arnold & Porter Kaye Scholer (Washington)

Articles

154 Bulletin

Diane E. Bieri, Jonathan Gleklen, Kelly Smith Fayne, Tim Frazer The US Supreme Court holds that “reverse payment” patent settlements between brand-name drug manufacturers and would-be generic competitors should be reviewed under the antitrust rule of reason (Actavis)

154

On Monday, June 17, the Supreme Court handed down a decision in FTC v. Actavis, Inc., bringing some clarity to the antitrust treatment of so-called reverse payment patent settlements between brand-name drug manufacturers and would-be generic competitors, but leaving many open questions as (...)

Send a message